Percutaneous atrial septal occluders: Are we there yet?
Dhaval R Parekh1,2,3, Zvonimir Krajcer1,2,3
1Department of Cardiology, Texas Heart Institute, Houston, Texas.
Abstract:
In a randomized, controlled trial, the Occlutech Figulla Flex II occluder was shown to be noninferior to the Amplatzer Septal Occluder. Both devices provided greater than 90% efficacy, with limited residual shunting and major complications. Although the risk of overall device erosions was low, larger and longer-term studies are needed to distinguish the differences between devices.
